Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEM NASDAQ:CPRX NASDAQ:TNGX NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$16.99-2.7%$16.20$5.68▼$19.43$1.05B-0.01888,343 shs80,895 shsCPRXCatalyst Pharmaceuticals$31.49$31.40$19.05▼$32.56$3.86B0.742.62 million shsN/ATNGXTango Therapeutics$25.78-3.3%$27.33$5.77▼$34.39$3.74B1.123.63 million shs157,935 shsVKTXViking Therapeutics$33.11-2.2%$34.02$22.96▼$43.15$3.86B0.662.61 million shs298,438 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics+0.23%-3.27%-5.05%+35.95%+112.27%CPRXCatalyst Pharmaceuticals0.00%0.00%-0.03%+11.43%+51.39%TNGXTango Therapeutics-0.26%-8.17%-15.32%+20.81%+299.55%VKTXViking Therapeutics-2.90%-10.78%-10.99%+8.08%+1.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$16.99-2.7%$16.20$5.68▼$19.43$1.05B-0.01888,343 shs80,895 shsCPRXCatalyst Pharmaceuticals$31.49$31.40$19.05▼$32.56$3.86B0.742.62 million shsN/ATNGXTango Therapeutics$25.78-3.3%$27.33$5.77▼$34.39$3.74B1.123.63 million shs157,935 shsVKTXViking Therapeutics$33.11-2.2%$34.02$22.96▼$43.15$3.86B0.662.61 million shs298,438 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics+0.23%-3.27%-5.05%+35.95%+112.27%CPRXCatalyst Pharmaceuticals0.00%0.00%-0.03%+11.43%+51.39%TNGXTango Therapeutics-0.26%-8.17%-15.32%+20.81%+299.55%VKTXViking Therapeutics-2.90%-10.78%-10.99%+8.08%+1.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 2.63Moderate Buy$32.1489.15% UpsideCPRXCatalyst Pharmaceuticals 2.56Moderate Buy$32.001.62% UpsideTNGXTango Therapeutics 2.75Moderate Buy$42.1563.51% UpsideVKTXViking Therapeutics 2.67Moderate Buy$97.00192.95% UpsideCurrent Analyst Ratings BreakdownLatest CGEM, CPRX, VKTX, and TNGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $39.007/20/2026VKTXViking Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/17/2026VKTXViking Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026TNGXTango Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $40.007/15/2026TNGXTango Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$46.007/8/2026CGEMCullinan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/29/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/29/2026TNGXTango Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $46.006/25/2026TNGXTango Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$27.00 ➝ $60.006/25/2026TNGXTango Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold6/12/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$6.92 per shareN/ACPRXCatalyst Pharmaceuticals$596.96M6.46$2.92 per share10.77$7.76 per share4.06TNGXTango Therapeutics$62.38M59.78N/AN/A$2.57 per share10.03VKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%8/6/2026 (Estimated)CPRXCatalyst Pharmaceuticals$214.33M$1.7418.1010.220.9637.08%35.76%31.31%8/5/2026 (Estimated)TNGXTango Therapeutics-$101.59M-$0.83N/AN/AN/AN/A-41.54%-33.44%8/4/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest CGEM, CPRX, VKTX, and TNGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026CGEMCullinan Therapeutics-$0.7994N/AN/AN/A$3.67 millionN/A8/5/2026Q2 2026CPRXCatalyst Pharmaceuticals$0.48N/AN/AN/A$155.79 millionN/A8/4/2026Q2 2026TNGXTango Therapeutics-$0.31N/AN/AN/A$1.56 millionN/A7/29/2026Q2 2026VKTXViking Therapeutics-$1.21N/AN/AN/AN/AN/A5/13/2026Q1 2026TNGXTango Therapeutics-$0.32-$0.32N/A-$0.32$0.58 millionN/A5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A10.2810.28CPRXCatalyst PharmaceuticalsN/A7.106.84TNGXTango TherapeuticsN/A27.3827.38VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%CPRXCatalyst Pharmaceuticals79.22%TNGXTango Therapeutics78.99%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics8.60%CPRXCatalyst Pharmaceuticals10.40%TNGXTango Therapeutics6.50%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableCPRXCatalyst Pharmaceuticals80122.42 million109.69 millionOptionableTNGXTango Therapeutics90144.65 million135.25 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableCGEM, CPRX, VKTX, and TNGX HeadlinesRecent News About These Companies3 Biotech Stocks With Massive Upside to Buy Before August Starts2 hours ago | 247wallst.comADAR1 Capital Management LLC Increases Position in Viking Therapeutics, Inc. $VKTXJuly 29 at 3:12 AM | marketbeat.comWall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull CaseJuly 28 at 5:42 PM | fool.comIs Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?July 28 at 12:38 PM | finance.yahoo.comCan These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?July 28 at 11:10 AM | zacks.comIs Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?July 28 at 10:31 AM | zacks.comRock Springs Capital Management LP Takes Position in Viking Therapeutics, Inc. $VKTXJuly 28 at 6:56 AM | marketbeat.comEversept Partners LP Takes Position in Viking Therapeutics, Inc. $VKTXJuly 28 at 6:32 AM | marketbeat.comViking Therapeutics (VKTX) to Release Quarterly Earnings on WednesdayJuly 28 at 2:42 AM | americanbankingnews.comGranahan Investment Management LLC Increases Stock Position in Viking Therapeutics, Inc. $VKTXJuly 25, 2026 | marketbeat.comHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketJuly 23, 2026 | finance.yahoo.comViking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Comes Into ViewJuly 23, 2026 | finance.yahoo.comViking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy NewsJuly 23, 2026 | finance.yahoo.comHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketJuly 23, 2026 | zacks.comViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsJuly 23, 2026 | finance.yahoo.comViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsJuly 23, 2026 | prnewswire.comViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026July 22, 2026 | finance.yahoo.comViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026July 22, 2026 | prnewswire.comViking Therapeutics (NASDAQ:VKTX) Rating Lowered to "Strong Sell" at Zacks ResearchJuly 22, 2026 | marketbeat.comViking Therapeutics (VKTX) to Release Earnings on WednesdayJuly 22, 2026 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Crosses Above 50 Day Moving Average - Here's What HappenedJuly 22, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGEM, CPRX, VKTX, and TNGX Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$16.99 -0.48 (-2.73%) As of 10:38 AM Eastern This is a fair market value price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Catalyst Pharmaceuticals NASDAQ:CPRX$31.49 0.00 (0.00%) As of 07/16/2026Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Tango Therapeutics NASDAQ:TNGX$25.78 -0.87 (-3.26%) As of 10:38 AM Eastern This is a fair market value price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.Viking Therapeutics NASDAQ:VKTX$33.11 -0.75 (-2.21%) As of 10:38 AM Eastern This is a fair market value price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory Welltower at 52-Week Highs—But Analysts Believe There's More to Come These 3 Stocks Have Soared in 2026—Can They Keep Climbing? UPS Just Gave Investors a Second Chance to Buy Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
